

Summary of the application: UV-treated baker's yeast (*Saccharomyces cerevisiae*)

Applicant: Lallemand Bio-Ingredients Division, 1620 Prefontaine Street, Montreal, Quebec, H1W2N8, Canada

The Novel Food subject to this application is UV-treated baker's yeast (*Saccharomyces cerevisiae*). Baker's yeast (*Saccharomyces cerevisiae*) is treated with ultraviolet light to induce the conversion of ergosterol to vitamin D2 (ergocalciferol). Vitamin D2 content in the yeast concentrate varies between 800 000-3 500 000 IU vitamin D/100 g (200-875 µg/g). The yeast may be inactivated. The yeast concentrate is blended with regular baker's yeast in order not to exceed the maximum level in the pre-packed fresh or dry yeast for home baking. Tan-coloured, free-flowing granules.

In 2014, Lallemand obtained the authorization to place the UV-treated baker's yeast (*Saccharomyces cerevisiae*) on the market as a novel food. In fact, in December 2013, EFSA concluded that the UV-treated baker's yeast is safe under the intended conditions of use (EFSA NDA Panel, 2014). The UV-treated baker's yeast was approved for use in the production of yeast-leavened bread and rolls, yeast-leavened fine bakery wares and food supplements as per Annex I of the Commission Implementing Decision (EU) 2014/396. An extension of use was authorised in 2018 by the Commission Implementing Regulation (EU) 2018/1018 following a request by Lallemand.

Lallemand, through its division Lallemand Bio-Ingredients, located at 1620 Prefontaine Street, H1W 2N8, Montréal, QC (Canada), is hereby requesting for an extension of use of the UV-treated baker's yeast as a novel food, as Lallemand intends to use the novel food in additional food categories. The detailed information on the food categories and the anticipated intake is provided in this application.

Based on the detailed intake assessment achieved, Lallemand estimates that the use of the novel food is safe under the proposed conditions of use. The target population is the general population, except for food supplements for which the target population is individuals aged 6 months and above.